Glaukos Business Model Canvas
Business Model Canvas for minimally invasive glaucoma implants and recurring revenue
Unlock the full strategic blueprint behind Glaukos’s business model: this concise Business Model Canvas shows how the company creates value with minimally invasive glaucoma surgeries, captures recurring revenue through implants and services, and leverages partnerships for market expansion. Ideal for investors, consultants, and founders seeking actionable insights—download the complete, editable Canvas in Word and Excel to benchmark and build winning strategies.
Partnerships
Ophthalmic KOLs and Surgeon Collaborators
Partner with leading glaucoma, cornea, and retina surgeons to guide product design and clinical protocols, leveraging a global network of thousands of treating physicians; KOLs drive adoption through peer influence and hands-on training. Continuous feedback loops from surgeon collaborators inform device iterations and therapy regimens, and co-authorship of studies—over 200 peer-reviewed publications as of 2024—strengthens clinical credibility.
Hospitals, ASCs, and Eye Care Networks
Partnering with hospitals, ASCs, and eye-care networks secures procedure access, standardized scheduling, and protocol alignment for MIGS and corneal cases, with ASCs performing roughly 60% of US cataract-related procedures. Site partnerships streamline workflows and inventory—ASCs often cut episode costs by about 30% versus hospital outpatient settings. Joint value analyses quantify ASC economics, and data sharing (eg, IRIS-type registries with tens of millions of records) improves outcomes tracking.
Academic and Research Institutions
Engage universities and eye institutes for preclinical research and translational science to leverage specialized labs and clinician networks. Access to models and biobanks such as UK Biobank (500,000 participants) and ocular tissue repositories accelerates target validation and pipeline progress. Joint grants and peer-reviewed publications expand scientific reach and credibility. Shared IP frameworks under Bayh-Dole-style tech transfer de-risk commercialization.
Manufacturing, CMOs, and Component Suppliers
Glaukos secures high-precision microfabrication, specialty polymers, drug APIs, and sterile packaging partners to sustain device integrity and regulatory compliance; contract manufacturing organizations provide GMP-scalable production and geographic redundancy for supply continuity. Supplier quality agreements and audit programs lock in traceability and change control, while co-engineering with suppliers reduces unit cost and improves device performance.
Regulators, Payers, and HTA Bodies
Proactive engagement with FDA, EMA and other agencies streamlines approvals and post‑market plans; Glaukos operates in 40+ countries as of 2024. Health‑economic collaborations build robust reimbursement dossiers. Payer pilots validate real‑world value and access. Ongoing dialogue secures coding, coverage and payment alignment.
- Regulatory alignment: FDA/EMA engagement
- HEOR: reimbursement dossiers
- Payer pilots: real‑world validation
- Coverage: coding and payment alignment
KOL-led surgeon partnerships and ASC networks accelerate adoption, cut cataract episode costs
KOL surgeon partnerships drive product design, training and adoption with co-authorship across 200+ peer‑reviewed papers (2024). Site partners (hospitals/ASCs) enable procedure access—ASCs perform ~60% of US cataract-related cases and can cut episode costs ~30%. CMOs, microfabrication and polymer suppliers ensure GMP scalability and supply redundancy; Glaukos operates in 40+ countries (2024).
| Partner type | Role | Key metric |
|---|---|---|
| KOLs/surgeons | Design/training | 200+ pubs (2024) |
| ASCs/hospitals | Procedure access | 60% US cataract cases |
| Suppliers/CMOs | GMP scale | 40+ countries |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Glaukos detailing customer segments (ophthalmologists, hospitals, patients), channels, value propositions (minimally invasive glaucoma devices, sustained drug delivery), revenue streams (device sales, consumables, licensing), cost structure, partners, key activities/resources, competitive advantages and a linked SWOT—designed for presentations, investor discussions and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Glaukos that condenses strategy into a one-page snapshot, saving hours of formatting and making it easy for teams to collaborate, compare models, and adapt quickly for boardrooms or fast deliverables.
Activities
R&D for MIGS, Corneal, and Retinal Therapies
Discover, design and optimize devices and therapeutics for chronic eye diseases, targeting glaucoma subpopulations within the roughly 80 million people affected worldwide. Iterate micro‑stent geometry, drug delivery kinetics and biomaterials to improve outflow and safety while reducing IOP. Develop retina candidates and corneal crosslinking innovations across preclinical and clinical stages. Maintain a balanced early‑to‑late pipeline to de‑risk commercialization.
Clinical Trials and Evidence Generation
Run multicenter studies to demonstrate safety, efficacy and durability; as of 2024 Glaukos’ MIGS implants have been used in over 150,000 patients and supported by dozens of peer‑reviewed publications. Generate comparative and health‑economic data for payers and guideline panels to show reduced medication burden and resource use. Maintain post‑market registries and real‑world evidence streams and publish in top journals (Ophthalmology, JAMA Ophthalmology) to drive clinical adoption.
Manufacturing and Quality Management
Operate GMP processes for sterile devices and drugs with validated aseptic lines and batch records supporting FY2024 revenue of $446.6 million. Enforce a rigorous QMS with full validation and traceability across serial numbers and lot records to meet regulatory audits. Scale capacity while holding yields and cost per unit flat, and continuous improvement programs cut defects and scrap through data-driven reductions.
Regulatory, Reimbursement, and Market Access
Regulatory, reimbursement, and market access activities include preparing submissions, labeling, and risk management files; building coding and coverage strategies supported by HEOR models; training sites on billing pathways; and monitoring compliance and post-market safety to secure adoption and payer coverage.
- Prepare regulatory dossiers and RMPs
- Develop HEOR-driven coding/coverage
- Train sites on billing
- Ongoing compliance & safety surveillance
Commercialization and Surgeon Education
Deploy direct sales teams focused on ophthalmology to drive adoption, deliver hands-on training, labs and proctoring for surgeons, support case planning and perioperative workflows, and maintain robust customer success and technical support to ensure procedure consistency and device uptime.
- Direct sales: ophthalmology-targeted
- Training: labs, proctoring
- Clinical support: case planning, peri-op
- Aftercare: customer success & technical support
Driving MIGS adoption: FY2024 revenue $446.6M, >150,000 patients treated
Discover, develop and manufacture MIGS devices and ophthalmic therapeutics; FY2024 revenue $446.6M and >150,000 MIGS patients implanted to date. Run multicenter trials and publish HEOR supporting reduced medication use. Maintain GMP, QMS, regulatory submissions and direct ophthalmology sales, training and post‑market surveillance.
| Metric | 2024 |
|---|---|
| Revenue | $446.6M |
| MIGS patients | >150,000 |
Delivered as Displayed
Business Model Canvas
The Glaukos Business Model Canvas you’re previewing is the actual deliverable—not a mockup. When you purchase, you’ll receive this exact document in full, formatted and ready to edit. No hidden pages or placeholders—what you see is what you’ll download and use. It’s structured for immediate presentation and strategic planning.
Business Model Canvas for minimally invasive glaucoma implants and recurring revenue
Unlock the full strategic blueprint behind Glaukos’s business model: this concise Business Model Canvas shows how the company creates value with minimally invasive glaucoma surgeries, captures recurring revenue through implants and services, and leverages partnerships for market expansion. Ideal for investors, consultants, and founders seeking actionable insights—download the complete, editable Canvas in Word and Excel to benchmark and build winning strategies.
Partnerships
Ophthalmic KOLs and Surgeon Collaborators
Partner with leading glaucoma, cornea, and retina surgeons to guide product design and clinical protocols, leveraging a global network of thousands of treating physicians; KOLs drive adoption through peer influence and hands-on training. Continuous feedback loops from surgeon collaborators inform device iterations and therapy regimens, and co-authorship of studies—over 200 peer-reviewed publications as of 2024—strengthens clinical credibility.
Hospitals, ASCs, and Eye Care Networks
Partnering with hospitals, ASCs, and eye-care networks secures procedure access, standardized scheduling, and protocol alignment for MIGS and corneal cases, with ASCs performing roughly 60% of US cataract-related procedures. Site partnerships streamline workflows and inventory—ASCs often cut episode costs by about 30% versus hospital outpatient settings. Joint value analyses quantify ASC economics, and data sharing (eg, IRIS-type registries with tens of millions of records) improves outcomes tracking.
Academic and Research Institutions
Engage universities and eye institutes for preclinical research and translational science to leverage specialized labs and clinician networks. Access to models and biobanks such as UK Biobank (500,000 participants) and ocular tissue repositories accelerates target validation and pipeline progress. Joint grants and peer-reviewed publications expand scientific reach and credibility. Shared IP frameworks under Bayh-Dole-style tech transfer de-risk commercialization.
Manufacturing, CMOs, and Component Suppliers
Glaukos secures high-precision microfabrication, specialty polymers, drug APIs, and sterile packaging partners to sustain device integrity and regulatory compliance; contract manufacturing organizations provide GMP-scalable production and geographic redundancy for supply continuity. Supplier quality agreements and audit programs lock in traceability and change control, while co-engineering with suppliers reduces unit cost and improves device performance.
Regulators, Payers, and HTA Bodies
Proactive engagement with FDA, EMA and other agencies streamlines approvals and post‑market plans; Glaukos operates in 40+ countries as of 2024. Health‑economic collaborations build robust reimbursement dossiers. Payer pilots validate real‑world value and access. Ongoing dialogue secures coding, coverage and payment alignment.
- Regulatory alignment: FDA/EMA engagement
- HEOR: reimbursement dossiers
- Payer pilots: real‑world validation
- Coverage: coding and payment alignment
KOL-led surgeon partnerships and ASC networks accelerate adoption, cut cataract episode costs
KOL surgeon partnerships drive product design, training and adoption with co-authorship across 200+ peer‑reviewed papers (2024). Site partners (hospitals/ASCs) enable procedure access—ASCs perform ~60% of US cataract-related cases and can cut episode costs ~30%. CMOs, microfabrication and polymer suppliers ensure GMP scalability and supply redundancy; Glaukos operates in 40+ countries (2024).
| Partner type | Role | Key metric |
|---|---|---|
| KOLs/surgeons | Design/training | 200+ pubs (2024) |
| ASCs/hospitals | Procedure access | 60% US cataract cases |
| Suppliers/CMOs | GMP scale | 40+ countries |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Glaukos detailing customer segments (ophthalmologists, hospitals, patients), channels, value propositions (minimally invasive glaucoma devices, sustained drug delivery), revenue streams (device sales, consumables, licensing), cost structure, partners, key activities/resources, competitive advantages and a linked SWOT—designed for presentations, investor discussions and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Glaukos that condenses strategy into a one-page snapshot, saving hours of formatting and making it easy for teams to collaborate, compare models, and adapt quickly for boardrooms or fast deliverables.
Activities
R&D for MIGS, Corneal, and Retinal Therapies
Discover, design and optimize devices and therapeutics for chronic eye diseases, targeting glaucoma subpopulations within the roughly 80 million people affected worldwide. Iterate micro‑stent geometry, drug delivery kinetics and biomaterials to improve outflow and safety while reducing IOP. Develop retina candidates and corneal crosslinking innovations across preclinical and clinical stages. Maintain a balanced early‑to‑late pipeline to de‑risk commercialization.
Clinical Trials and Evidence Generation
Run multicenter studies to demonstrate safety, efficacy and durability; as of 2024 Glaukos’ MIGS implants have been used in over 150,000 patients and supported by dozens of peer‑reviewed publications. Generate comparative and health‑economic data for payers and guideline panels to show reduced medication burden and resource use. Maintain post‑market registries and real‑world evidence streams and publish in top journals (Ophthalmology, JAMA Ophthalmology) to drive clinical adoption.
Manufacturing and Quality Management
Operate GMP processes for sterile devices and drugs with validated aseptic lines and batch records supporting FY2024 revenue of $446.6 million. Enforce a rigorous QMS with full validation and traceability across serial numbers and lot records to meet regulatory audits. Scale capacity while holding yields and cost per unit flat, and continuous improvement programs cut defects and scrap through data-driven reductions.
Regulatory, Reimbursement, and Market Access
Regulatory, reimbursement, and market access activities include preparing submissions, labeling, and risk management files; building coding and coverage strategies supported by HEOR models; training sites on billing pathways; and monitoring compliance and post-market safety to secure adoption and payer coverage.
- Prepare regulatory dossiers and RMPs
- Develop HEOR-driven coding/coverage
- Train sites on billing
- Ongoing compliance & safety surveillance
Commercialization and Surgeon Education
Deploy direct sales teams focused on ophthalmology to drive adoption, deliver hands-on training, labs and proctoring for surgeons, support case planning and perioperative workflows, and maintain robust customer success and technical support to ensure procedure consistency and device uptime.
- Direct sales: ophthalmology-targeted
- Training: labs, proctoring
- Clinical support: case planning, peri-op
- Aftercare: customer success & technical support
Driving MIGS adoption: FY2024 revenue $446.6M, >150,000 patients treated
Discover, develop and manufacture MIGS devices and ophthalmic therapeutics; FY2024 revenue $446.6M and >150,000 MIGS patients implanted to date. Run multicenter trials and publish HEOR supporting reduced medication use. Maintain GMP, QMS, regulatory submissions and direct ophthalmology sales, training and post‑market surveillance.
| Metric | 2024 |
|---|---|
| Revenue | $446.6M |
| MIGS patients | >150,000 |
Delivered as Displayed
Business Model Canvas
The Glaukos Business Model Canvas you’re previewing is the actual deliverable—not a mockup. When you purchase, you’ll receive this exact document in full, formatted and ready to edit. No hidden pages or placeholders—what you see is what you’ll download and use. It’s structured for immediate presentation and strategic planning.
Description
Business Model Canvas for minimally invasive glaucoma implants and recurring revenue
Unlock the full strategic blueprint behind Glaukos’s business model: this concise Business Model Canvas shows how the company creates value with minimally invasive glaucoma surgeries, captures recurring revenue through implants and services, and leverages partnerships for market expansion. Ideal for investors, consultants, and founders seeking actionable insights—download the complete, editable Canvas in Word and Excel to benchmark and build winning strategies.
Partnerships
Ophthalmic KOLs and Surgeon Collaborators
Partner with leading glaucoma, cornea, and retina surgeons to guide product design and clinical protocols, leveraging a global network of thousands of treating physicians; KOLs drive adoption through peer influence and hands-on training. Continuous feedback loops from surgeon collaborators inform device iterations and therapy regimens, and co-authorship of studies—over 200 peer-reviewed publications as of 2024—strengthens clinical credibility.
Hospitals, ASCs, and Eye Care Networks
Partnering with hospitals, ASCs, and eye-care networks secures procedure access, standardized scheduling, and protocol alignment for MIGS and corneal cases, with ASCs performing roughly 60% of US cataract-related procedures. Site partnerships streamline workflows and inventory—ASCs often cut episode costs by about 30% versus hospital outpatient settings. Joint value analyses quantify ASC economics, and data sharing (eg, IRIS-type registries with tens of millions of records) improves outcomes tracking.
Academic and Research Institutions
Engage universities and eye institutes for preclinical research and translational science to leverage specialized labs and clinician networks. Access to models and biobanks such as UK Biobank (500,000 participants) and ocular tissue repositories accelerates target validation and pipeline progress. Joint grants and peer-reviewed publications expand scientific reach and credibility. Shared IP frameworks under Bayh-Dole-style tech transfer de-risk commercialization.
Manufacturing, CMOs, and Component Suppliers
Glaukos secures high-precision microfabrication, specialty polymers, drug APIs, and sterile packaging partners to sustain device integrity and regulatory compliance; contract manufacturing organizations provide GMP-scalable production and geographic redundancy for supply continuity. Supplier quality agreements and audit programs lock in traceability and change control, while co-engineering with suppliers reduces unit cost and improves device performance.
Regulators, Payers, and HTA Bodies
Proactive engagement with FDA, EMA and other agencies streamlines approvals and post‑market plans; Glaukos operates in 40+ countries as of 2024. Health‑economic collaborations build robust reimbursement dossiers. Payer pilots validate real‑world value and access. Ongoing dialogue secures coding, coverage and payment alignment.
- Regulatory alignment: FDA/EMA engagement
- HEOR: reimbursement dossiers
- Payer pilots: real‑world validation
- Coverage: coding and payment alignment
KOL-led surgeon partnerships and ASC networks accelerate adoption, cut cataract episode costs
KOL surgeon partnerships drive product design, training and adoption with co-authorship across 200+ peer‑reviewed papers (2024). Site partners (hospitals/ASCs) enable procedure access—ASCs perform ~60% of US cataract-related cases and can cut episode costs ~30%. CMOs, microfabrication and polymer suppliers ensure GMP scalability and supply redundancy; Glaukos operates in 40+ countries (2024).
| Partner type | Role | Key metric |
|---|---|---|
| KOLs/surgeons | Design/training | 200+ pubs (2024) |
| ASCs/hospitals | Procedure access | 60% US cataract cases |
| Suppliers/CMOs | GMP scale | 40+ countries |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Glaukos detailing customer segments (ophthalmologists, hospitals, patients), channels, value propositions (minimally invasive glaucoma devices, sustained drug delivery), revenue streams (device sales, consumables, licensing), cost structure, partners, key activities/resources, competitive advantages and a linked SWOT—designed for presentations, investor discussions and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Glaukos that condenses strategy into a one-page snapshot, saving hours of formatting and making it easy for teams to collaborate, compare models, and adapt quickly for boardrooms or fast deliverables.
Activities
R&D for MIGS, Corneal, and Retinal Therapies
Discover, design and optimize devices and therapeutics for chronic eye diseases, targeting glaucoma subpopulations within the roughly 80 million people affected worldwide. Iterate micro‑stent geometry, drug delivery kinetics and biomaterials to improve outflow and safety while reducing IOP. Develop retina candidates and corneal crosslinking innovations across preclinical and clinical stages. Maintain a balanced early‑to‑late pipeline to de‑risk commercialization.
Clinical Trials and Evidence Generation
Run multicenter studies to demonstrate safety, efficacy and durability; as of 2024 Glaukos’ MIGS implants have been used in over 150,000 patients and supported by dozens of peer‑reviewed publications. Generate comparative and health‑economic data for payers and guideline panels to show reduced medication burden and resource use. Maintain post‑market registries and real‑world evidence streams and publish in top journals (Ophthalmology, JAMA Ophthalmology) to drive clinical adoption.
Manufacturing and Quality Management
Operate GMP processes for sterile devices and drugs with validated aseptic lines and batch records supporting FY2024 revenue of $446.6 million. Enforce a rigorous QMS with full validation and traceability across serial numbers and lot records to meet regulatory audits. Scale capacity while holding yields and cost per unit flat, and continuous improvement programs cut defects and scrap through data-driven reductions.
Regulatory, Reimbursement, and Market Access
Regulatory, reimbursement, and market access activities include preparing submissions, labeling, and risk management files; building coding and coverage strategies supported by HEOR models; training sites on billing pathways; and monitoring compliance and post-market safety to secure adoption and payer coverage.
- Prepare regulatory dossiers and RMPs
- Develop HEOR-driven coding/coverage
- Train sites on billing
- Ongoing compliance & safety surveillance
Commercialization and Surgeon Education
Deploy direct sales teams focused on ophthalmology to drive adoption, deliver hands-on training, labs and proctoring for surgeons, support case planning and perioperative workflows, and maintain robust customer success and technical support to ensure procedure consistency and device uptime.
- Direct sales: ophthalmology-targeted
- Training: labs, proctoring
- Clinical support: case planning, peri-op
- Aftercare: customer success & technical support
Driving MIGS adoption: FY2024 revenue $446.6M, >150,000 patients treated
Discover, develop and manufacture MIGS devices and ophthalmic therapeutics; FY2024 revenue $446.6M and >150,000 MIGS patients implanted to date. Run multicenter trials and publish HEOR supporting reduced medication use. Maintain GMP, QMS, regulatory submissions and direct ophthalmology sales, training and post‑market surveillance.
| Metric | 2024 |
|---|---|
| Revenue | $446.6M |
| MIGS patients | >150,000 |
Delivered as Displayed
Business Model Canvas
The Glaukos Business Model Canvas you’re previewing is the actual deliverable—not a mockup. When you purchase, you’ll receive this exact document in full, formatted and ready to edit. No hidden pages or placeholders—what you see is what you’ll download and use. It’s structured for immediate presentation and strategic planning.
